⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
prnewswire.com
NVS
BOC Group Named a Challenger in the 2026 Gartner® Magic Quadrant™ for Digital Twin of an Organization Platforms
prnewswire.com
CSCO
NVS
BOC Group Named a Challenger in the 2026 Gartner® Magic Quadrant™ for Digital Twin of an Organization Platforms
prnewswire.com
CSCO
NVS
Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
globenewswire.com
INBX
LLY
PFE
NVS
BMY
EXEL
JNJ
AZN
JAZZ
TLRY
THE SKIN OF COLOR SOCIETY (SOCS) UNITES 21 GLOBAL ORGANIZATIONS TO ADVANCE SKIN OF COLOR DERMATOLOGY
prnewswire.com
NVS
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
globenewswire.com
NVS
Paralyzed Veterans of America Takes 2026 Healthcare Summit + Expo to Vegas to Advance Care for Spinal Cord Injury, MS, and ALS
prnewswire.com
BIIB
NVS
Specialty Pharmaceuticals Market (2026-2031) - Rising Prevalence of Chronic and Rare Diseases Drives Growth
globenewswire.com
ABBV
AMGN
AZN
BIIB
BMRA
BMY
JNJ
MRK
NVS
PFE
REGN
SNY
TEVA
VRTX
Cytotoxic Drugs Market Report Now Available — Forecasts Market Growth from $16.21B (2026) to $21.06B by 2031, Profiling Pfizer, Roche, Novartis, AstraZeneca, Sanofi, and 15 Other Key Players
globenewswire.com
PFE
NVS
AZN
SNY
LLY
JNJ
MRK
AMGN
BIIB
GILD
BMY
ABBV
XRAY
VTRS
TEVA
SUN
Breast Cancer Continues to Impact Communities; Milwaukee Rallies Together to Take Action at Susan G. Komen® MORE THAN PINK Walk
businesswire.com
FOX
PEP
BAC
LLY
NVS
NTRA